ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Mediated Amyloidosis (ATTR)
Conditions
Transthyretin Mediated Amyloidosis (ATTR)
Trial Timeline
Jun 1, 2010 → Feb 1, 2012
NCT ID
NCT01148953About ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Transthyretin Mediated Amyloidosis (ATTR). The current trial status is completed. This product is registered under clinical trial identifier NCT01148953. Target conditions include Transthyretin Mediated Amyloidosis (ATTR).
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01148953 | Phase 1 | Completed |
Competing Products
20 competing products in Transthyretin Mediated Amyloidosis (ATTR)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |